human antichimeric antibody haca develop patients undergoing autoimmune disease therapy drug infliximab drug cause patient develop antibodies medicine termed hacas incidence developing antibodies highest patients receiving intermittent therapy infliximab lowest patient receiving continuous therapy concomitant immunosuppressive therapy suggest presence antibodies causes decrease efficacy infliximab increased risk infusion reactions monoclonal article stub help wikipedia expanding httpsenwikipediaorgwikihumanantichimericantibody